Cover Image
市場調查報告書

難辨梭狀芽孢桿菌傳染病(CDI)的流行病學的預測 ∼2024年

EpiCast Report: Clostridium Difficile Infection (CDI) - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 345023
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
難辨梭狀芽孢桿菌傳染病(CDI)的流行病學的預測 ∼2024年 EpiCast Report: Clostridium Difficile Infection (CDI) - Epidemiology Forecast to 2024
出版日期: 2015年10月13日 內容資訊: 英文 60 Pages
簡介

難辨梭狀芽孢桿菌傳染病(CDI)主要來自糞口途徑感染。主要的症狀,有水瀉、食慾不振、噁心等輕症狀,到低白蛋白血、腹部壓痛等重症狀。難辨梭狀芽孢桿菌傳染病發病數量預計從2014年的686,540件到2024年達825,021件。今後10年年複合成長率成為2.02%。在7大市場中以美國數量最大。

本報告提供難辨梭狀芽孢桿菌傳染病市場相關調查、風險因素等概要與7大市場(美國、法國、德國、義大利、西班牙、英國、日本)的過去10年的疫情趨勢、性別、各年齡的預測彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
  • 全球的趨勢
    • 7大市場發病率
    • 流行病學的各相關發病數量
    • 各復發發病數量
  • 預測方法
    • 採用的資訊來源
    • 未採用的資訊來源
    • 假設與預測方法
  • 流行病學的預測
    • 確診發病數量
    • 各年齡
    • 性別
    • 年齡標準化的發病率
  • 考察
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考文件
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER095-15

Clostridium difficile infections (CDI) are primarily transmitted through the fecal-oral route. There are two major sources of CDI: healthcare-associated CDI (HA-CDI) and community-associated CDI (CA-CDI). The typical clinical symptoms of CDI range from watery diarrhea, anorexia, and nausea, to hypoalbuminemia and abdominal tenderness in severe cases. Though suspected in all patients with antibiotic-associated diarrhea, the confirmatory diagnosis of CDI is primarily based on the combination of clinical features exhibited by the patient and the results of various laboratory tests including stool tests, as well as, in certain rare scenarios, endoscopy or radiologic tests. Recurrence and complications of CDI usually pose grave challenges for the treatment and management of this condition and occur in about 20-30% of the patients treated successfully for their first episode.

GlobalData epidemiologists predict that the diagnosed incident cases of all-CDI will grow from 686,540 cases in 2014 to 825,021 cases in 2024, at an Annual Growth Rate (AGR) of 2.02% over the 10-year forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of all-CDI in the 7MM.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years). The term all-CDI is defined as any instance of suspected CDI and diarrhea, with stool samples testing positive for toxin A, B, or both (enzyme immunoassay [EIA], cytotoxicity test, or polymerase chain reaction [PCR]) or revealing the presence of toxin-producing C. difficile, and includes both HA-CDI and CA-CDI. The report also provides the 10-year epidemiology forecast for the all-CDI cases segmented by epidemiological association into HA-CDI and CA-CDI. Additionally, the report provides a 10-year epidemiological forecast for the recurrent all-CDI cases with a further segmentation by number of recurrences.

Scope

  • The Clostridium difficile infection (CDI) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years).
  • The CDI epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Clostridium Difficile Infection (CDI) EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CDI market.
  • Quantify patient populations in the global CDI market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CDI therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 7MM: Diagnosed Incidence Rates
    • 3.3.2. 7MM: Diagnosed Incident Cases by Epidemiological Association
    • 3.3.3. 7MM: Diagnosed Incident Cases by Recurrences
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of CDI (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of All-CDI
    • 3.5.2. Age-Specific Diagnosed Incident Cases of All-CDI
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of All-CDI
    • 3.5.4. Age-Standardized Diagnosed Incidence Rate of All-CDI
    • 3.5.5. Recurrent CDI Cases
    • 3.5.6. Diagnosed Incident Cases of All-CDI by Epidemiological Association
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for CDI
  • Table 2: Definitions of CDI Segmentations
  • Table 3: 7MM, Sources of CDI Diagnosed Incidence Data
  • Table 4: 7MM, Sources of CDI Recurrence Rates
  • Table 5: 7MM, Sources of CDI Epidemiological Association
  • Table 6: 7MM, Sources Not Used in Epidemiological Analysis of CDI
  • Table 7: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 8: 7MM, Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014.
  • Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014

List of Figures

  • Figure 1: Incidence Rate for CDI in the 7MM, 2014
  • Figure 2: Case Flow Map for the US
  • Figure 3: Case Flow Map for the 5EU and Japan
  • Figure 4: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Figure 5: Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014
  • Figure 6: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014
  • Figure 7: 7MM, Age-Standardized Diagnosed Incidence Rates of All-CDI, 2014
  • Figure 8: 5EU and Japan, Recurrent CDI Cases, Ages ≥18 Years, N, 2014
  • Figure 9: US, Diagnosed Incident Cases of CDI Stratified by Recurrence, Ages ≥18 Years, N, 2014
  • Figure 10: 5EU and Japan, Diagnosed Incident Cases of All-CDI Stratified by Epidemiological Association, Ages ≥18 Years, N, 2014
  • Figure 11: US, Diagnosed Incident Cases of All-CDI by Epidemiological Association, Ages ≥18 Years, N, 2014
Back to Top